• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
RETA

RETA

Reata Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD172.36

+0.04 (+0.02%)

Company Profile

CEO

J. Warren Huff

IPO Date

2016-05-26

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$172.34

Prev. Close

$172.32

Day Low

$172.32

Day High

$172.46

52W Low

$21.83

52W High

$172.46

Market Cap

$6.57B

Volume

1.91M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

56.9%

Avg Negative

9.1%

Avg Neutral

34.1%

News Feed

Reata Pharmaceuticals, Inc. (RETA) Soars 5.3%: Is Further Upside Left in the Stock?

Zacks Investment Research·6/28/2021·↑ positive

Reata: Big Run-Up Toward Approval

Seeking Alpha·6/16/2021·↑ positive

Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference

GlobeNewsWire·6/7/2021·↑ positive

Reata (RETA) Soars on Potential Omaveloxolone NDA Filing

Zacks Investment Research·5/20/2021·↓ negative

Why Reata Pharmaceuticals Stock Is Skyrocketing Today

The Motley Fool·5/19/2021·↑ positive

Here's why Reata Pharmaceuticals gained 20% on Wednesday

Invezz·5/19/2021·↑ positive

Reata Pharmaceuticals (RETA) Stock: Over 14% Increase Pre-Market Explanation

Pulse2·5/19/2021·↑ positive

Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich's Ataxia

GlobeNewsWire·5/19/2021·↓ negative

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/8/2021·↓ negative

Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs

GlobeNewsWire·5/6/2021·↑ positive